UCB S.A., a biopharmaceutical company, through its subsidiaries, engages in the research, development, and commercialization of pharmaceutical and biotechnology products. Its products are used for the treatment of various diseases, such as central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders, and oncology. Its products include Keppra for partial onset seizures; Metadate-CD/Equasym XL for use in the treatment of attention deficit hyperactivity disorders; Nootropil, which is a cerebral function regulator; Xyzal and Zyrtec used in the treatment of allergic conditions, such as seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria; Tussionex, a cough suppressant; and Lortab tablets and Lortab Elixir for pain relief. The company’s products also Somatostatin-UCB for the treatment of patients suffering from haemorrhaging of the oesophagus and post-operative gastro-intestinal fistulas; Stogar, a histamine blocker for use in the treatment of gastric ulcers, duodenal ulcers, stomal ulcers, and gastric mucosal lesions; Kentera, a transdermal patch treatment; and BUP-4 used in the treatment of urinary incontinence in neurogenic bladder, neurologic pollakiuria, unstable bladder, and irritable bladder diseases or conditions. UCB S.A. has collaborative agreements with Amgen; ChemBridge Corp.; Combinature; Daiichi Pharmaceutical Company; GlaxoSmithKline; ImClone Systems, Inc.; Immunomedics; Lonza A.G; Millennium; Pfizer; Sareum; Seattle Genetics; Biogen Idec, Inc.; and Wyeth. It has operations primarily in the United States, Europe, and Japan. The company was founded in 1928 and is headquartered in Brussels, Belgium.